The Search for the Perfect Agent for Anemia Management in Chronic Kidney Disease.
作者信息
Locatelli Francesco, Del Vecchio Lucia
机构信息
Past Director, Department of Nephrology and Dialysis, Alessandro Manzoni Hospital, Azienda Socio Sanitaria Territoriale Lecco, Lecco, Italy.
Department of Nephrology and Dialysis, Sant'Anna Hospital, Azienda Socio Sanitaria Territoriale Lariana, Como, Italy.
出版信息
J Am Soc Nephrol. 2022 Apr;33(4):662-664. doi: 10.1681/ASN.2022020173.
Abstract
摘要
相似文献
1
The Search for the Perfect Agent for Anemia Management in Chronic Kidney Disease.
J Am Soc Nephrol. 2022 Apr;33(4):662-664. doi: 10.1681/ASN.2022020173.
2
A New Approach to the Management of Anemia in CKD Patients: A Review on Roxadustat.
Adv Ther. 2017 Apr;34(4):848-853. doi: 10.1007/s12325-017-0508-9. Epub 2017 Mar 13.
3
Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
J Pharmacol Exp Ther. 2020 Aug;374(2):342-353. doi: 10.1124/jpet.120.265181. Epub 2020 Jun 2.
4
A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.
Nephron. 2020;144(8):372-382. doi: 10.1159/000508100. Epub 2020 Jun 24.
5
An evaluation of roxadustat for the treatment of anemia associated with chronic kidney disease.
Expert Opin Pharmacother. 2022 Jan;23(1):19-28. doi: 10.1080/14656566.2021.1993821. Epub 2021 Oct 27.
6
Whether Prolyl Hydroxylase Blocker-Roxadustat-In the Treatment of Anemia in Patients with Chronic Kidney Disease Is the Future?
Int J Environ Res Public Health. 2021 Feb 8;18(4):1612. doi: 10.3390/ijerph18041612.
7
Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.
Nephrol Dial Transplant. 2015 Oct;30(10):1665-73. doi: 10.1093/ndt/gfv302. Epub 2015 Aug 3.
8
Roxadustat in the treatment of anaemia in chronic kidney disease.
Expert Opin Investig Drugs. 2018 Jan;27(1):125-133. doi: 10.1080/13543784.2018.1417386. Epub 2017 Dec 25.
9
Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study.
J Am Soc Nephrol. 2022 Apr;33(4):850-866. doi: 10.1681/ASN.2020111638.
10
Roxadustat for the treatment of anemia in patients with chronic kidney diseases: a meta-analysis.
Aging (Albany NY). 2021 Jun 11;13(13):17914-17929. doi: 10.18632/aging.203143.
引用本文的文献
1
Anemia and iron deficiency in post-kidney transplantation: an unsolved challenge.
Clin Kidney J. 2025 Aug 19;18(9):sfaf252. doi: 10.1093/ckj/sfaf252. eCollection 2025 Sep.
2
A novel scenario in the therapeutic management of anemia of chronic kidney disease: placement and use of roxadustat.
J Nephrol. 2024 May;37(4):1107-1119. doi: 10.1007/s40620-023-01849-9. Epub 2024 Jan 8.
3
Activation of HIF-1α C-terminal transactivation domain protects against hypoxia-induced kidney injury through hexokinase 2-mediated mitophagy.
Cell Death Dis. 2023 May 24;14(5):339. doi: 10.1038/s41419-023-05854-5.
4
Clinical Management of Hemodialyzed Patients: From Pharmacological Interventions to Advanced Technologies.
J Clin Med. 2022 Jul 25;11(15):4310. doi: 10.3390/jcm11154310.
Zotero 插件